Pyrazolyl nicotinamides and pyrimidine carboxamides as CAMK2 inhibitors
Novel pyrazolyl nicotinamides and pyrimidine carboxamides serve as effective inhibitors of CAMK2 kinases, addressing the inadequacies of current treatments for conditions like heart failure and cardiac arrhythmias, offering therapeutic benefits across multiple disorders.
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- BRISTOL MYERS SQUIBB CO
- Filing Date
- 2025-11-18
- Publication Date
- 2026-05-28
AI Technical Summary
Current treatments for diseases associated with Calcium calmodulin dependent protein kinase 2 (CAMK2) kinases, such as heart failure, fibrosis, and cardiac arrhythmias, are inadequate, and there is a need for more effective inhibitors to manage these conditions.
Development of novel pyrazolyl nicotinamides and pyrimidine carboxamides that act as selective inhibitors of CAMK2 isoforms, including CAMK2D, CAMK2A, CAMK2B, and CAMK2G, which can be used in pharmaceutical compositions to treat these diseases.
The compounds effectively inhibit CAMK2 activity, providing therapeutic benefits in treating conditions like heart failure, fibrosis, and cardiac arrhythmias, with potential applications in other disorders including diabetes, asthma, and anxiety.
Smart Images
Figure IMGF000003_0001 
Figure IMGF000006_0001 
Figure IMGF000006_0002